Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total transaction of $214,755.70. Following the transaction, the director owned 5,373 shares of the company’s stock, valued at $367,244.55. The trade was a 36.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raymond Anderson also recently made the following trade(s):
- On Tuesday, August 25th, Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34.
Monopar Therapeutics Stock Performance
MNPR stock traded up $2.92 during midday trading on Wednesday, hitting $72.81. The company’s stock had a trading volume of 189,611 shares, compared to its average volume of 143,006. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82. The firm’s 50-day moving average is $88.66 and its 200-day moving average is $77.40.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, research analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have weighed in on MNPR shares. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Barclays restated an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. BTIG Research lifted their target price on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $122.00.
Get Our Latest Analysis on MNPR
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in MNPR. Siren L.L.C. increased its holdings in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the period. Bank of New York Mellon Corp raised its stake in Monopar Therapeutics by 21.2% during the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after acquiring an additional 13,761 shares during the period. Walleye Capital LLC purchased a new position in Monopar Therapeutics during the first quarter valued at approximately $3,458,000. Finally, Bank of America Corp DE lifted its holdings in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares in the last quarter. 1.83% of the stock is owned by hedge funds and other institutional investors.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.
Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.
Featured Articles
- Five stocks we like better than Monopar Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
